Compared to its wild type counterpart, mutant BRAFV600E has an increased phosphorylation activity on the mitogen-activated protein kinases 1 and 2 (MEK1 and MEK2), which in turn activate the extracellularly regulated kinases 1 and 2 (ERK1 and ERK2), thereby activating the mitogen-activated protein kinase (MAPK) pathway to promote cancer [5]. The gene discussed is MAPK1; the disease is cancer.